fashion -WSS

fashion

author：focus 2025-08-23 05:04:16 - browse：26

FDA's Peter Marks talks with STAT's Adam Feuerstein — Peter Marks, the FDA's top regulator of gene therapies (right), speaks with STAT's Adam Feuerstein in San Francisco. Sarah Gonzalez/Peopletography for STAT

SAN FRANCISCO — Peter Marks, the Food and Drug Administration’s top regulator of gene therapies, seems very comfortable with granting some form of full approval to Elevidys, the Sarepta Therapeutics gene therapy for Duchenne muscular dystrophy, based on his comments to me on Monday night during our “fireside chat” at a STAT event.

To be clear, Marks declined to comment specifically about the ongoing FDA review of Elevidys. I tried. However, Marks described a “hypothetical case” in the context of my Sarepta questions that clearly suggested the failure of an Elevidys confirmatory study in October didn’t bother him all that much.

“Hypothetically, if you had a product that used an aggregate scale and all of the components of that aggregate scale looked pretty good, or nearly all of them look pretty good, but the aggregate, for various reasons, didn’t come out perfectly. We approved products based on that,” Marks told me.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Women's World Cup brings attention to abuse in soccer

entertainment

WSS

Florida health officials providing scant details on measles cases

Blinken talks high

Longer MASH drug regimen improved liver, Akero study finds

The untold story of TV’s first prescription drug ad

Cuban government calls US nuclear submarine stop a 'provocative escalation'

After half a century, Israel moves to evict squatter from his cave home on the beach

leisure time

fashion

leisure time

Medicare proposal to cover medical devices draws a mixed reaction

Families look for replacement for GSK asthma drug Flovent

In Memoriam: Notable people who died in 2023

Readout Newsletter: BridgeBio, Akero, and human embryo models

Bright Health sells Medicare Advantage business to Molina

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

Guidelines to prevent youth baseball injuries need more muscle

Streamlined flu vaccines recommended by FDA advisory panel

Hollywood unions extend contract negotiations for actors

Britney Spears to release memoir, 'The Woman In Me,' later this year

focus

Pregnant women don't need prenatal multivitamins, study concludes

Sickle cell gene therapy cures need to be accessible in Africa

Iran's president begins a rare visit to Africa 'to promote economic diplomacy'

$1 billion proposal to grow Boston, Massachusetts biotech

The debate over Covid

Change Healthcare: What is it, why does its cyberattack matter?

entertainment

hotspot

entertainment

hotspot